Advances in Cancer Biology-Metastasis is an emerging journal published by Elsevier, aimed at advancing our understanding of the complexities of cancer biology, with a specific focus on the mechanisms and pathways related to metastasis. With an E-ISSN of 2667-3940, this journal offers a platform for researchers, professionals, and students in the fields of Cancer Research and Cell Biology to disseminate innovative findings and discuss novel therapeutic approaches. Though currently classified in the Q4 quartile across both Cancer Research and Cell Biology categories, the journal aspires to enhance its impact through rigorous peer review and high-quality publication. Positioned to cover the years from 2021 to 2024, it seeks to bridge gaps in foundational knowledge and promote collaborative research efforts that could pivot the current understanding of cancer metastasis. Researchers are encouraged to take advantage of this platform to advocate for advancements in cancer biology, making significant contributions that can influence both academic and clinical practices.

Welcome to Critical Reviews in Biochemistry and Molecular Biology, a premier academic journal published by Taylor & Francis Ltd, dedicated to advancing the fields of biochemistry and molecular biology. With an impressive impact factor and a Q1 ranking in both Biochemistry and Molecular Biology for 2023, this journal serves as a vital resource for researchers, professionals, and students eager to engage with cutting-edge reviews and analyses that synthesize the latest developments in these dynamic areas of study. Since its inception in 1972, the journal has maintained a commitment to high-quality scholarship, providing a platform for critical discussions that accelerate the discovery and understanding of biochemical processes and molecular interactions. Although not open access, its robust editorial peer-review process ensures that published articles meet the highest standards of scientific rigor, making it a trusted source for the scientific community. As we continue to converge toward 2024, we invite you to explore the extensive array of topics and findings that have shaped contemporary biochemistry and molecular biology.

Transcription-Austin is a leading academic journal published by Taylor & Francis Inc., dedicated to the rapidly evolving fields of biochemistry, biotechnology, and genetics. As a testament to its significance in the academic community, it has been ranked in the Q1 category across all three fields, establishing itself as a premier platform for high-quality research and innovative findings since its inception in 2010. With an H-index reflecting robust academic influence, Transcription-Austin invites contributions that enhance our understanding of transcriptional processes and their implications in various biological contexts. Researchers and professionals alike will find value in its rigorous peer-reviewed articles, which set the stage for future advancements in molecular biology. The journal is based in the United Kingdom and provides a critical resource for scholars aiming to disseminate cutting-edge research to a global audience.

FEBS LETTERS, published by Wiley, is a prestigious journal that has firmly established its place in the fields of biochemistry, biophysics, genetics, molecular biology, cell biology, and structural biology. With an esteemed history dating back to 1968, this journal continues to be a vital resource for researchers and professionals involved in the biological sciences. It boasts impressive quartile rankings, including Q1 statuses in several categories such as Biochemistry and Genetics, reflecting its high impact factor and significant contribution to scientific discourse. FEBS LETTERS provides a platform for innovative findings and critical reviews, fostering the exchange of knowledge and ideas within the scientific community. Although it operates under a subscription model, the journal ensures broad dissemination of groundbreaking research through its rigorous peer-review process. The vibrant discussions encouraged by articles published in FEBS LETTERS aim to inspire current and future generations of scientists to push the boundaries of biological understanding, making it an indispensable resource for anyone dedicated to advancing their knowledge in these dynamic fields.

BIOCHEMICAL GENETICS, published by Springer/Plenum Publishers, is a prominent journal in the fields of biochemistry, genetics, and molecular biology, with a substantial impact on the scientific community since its inception in 1967. The journal holds a significant position within various academic quartiles, ranking Q2 in Ecology, Evolution, Behavior and Systematics, and Q3 in Biochemistry, Genetics, and Medicine (miscellaneous), among others, demonstrating its diverse and interdisciplinary reach. With an ISSN of 0006-2928 and an E-ISSN of 1573-4927, it is recognized for contributing critical research insights and methodologies that drive the fields of biochemical genetics forward. Although it is not an Open Access journal, it provides vital access options and resources for researchers globally, facilitating the dissemination of knowledge across institutions. Positioned within the competitive landscape of Scopus rankings, it maintains respectable standings across its focused areas, making it an invaluable resource for researchers, professionals, and students seeking to deepen their understanding of genetic mechanisms and biochemical processes.

MOLECULAR GENETICS AND GENOMICS is a distinguished journal published by SPRINGER HEIDELBERG that serves as a pivotal platform for the communication of cutting-edge research and developments in the fields of genetics, molecular biology, and medicine. With an ISSN of 1617-4615 and an E-ISSN of 1617-4623, this journal has established itself since its inception in 1994 as a significant resource for researchers aiming to explore the complexities of genetic interactions and their implications in various biological systems. The journal is indexed in Scopus, with respectable rankings in the Genetics, Molecular Biology, and Biochemistry categories, showcasing its position within the academic community. It is categorized in the 2023 rankings as Q3 in Genetics, Q2 in Medicine (miscellaneous), and Q3 in Molecular Biology, indicating its relevance and quality in the scientific discourse. The journal also promotes open access, ensuring that researchers and professionals can easily share and advance knowledge in the rapidly evolving disciplines of molecular genetics and genomics. As the journal continues to bridge the gap between experimental and theoretical research, it presents a vital space for innovation, fostering collaborations and scholarly exchange among its readership.

GENOME is a leading peer-reviewed journal published by Canadian Science Publishing, dedicated to advancing the field of genetics, biotechnology, and molecular biology. With a strong commitment to disseminating high-quality research, GENOME has earned a reputable spot in the academic community, boasting a Q2 classification in Biotechnology and Medicine (miscellaneous), and a Q3 rank in Genetics and Molecular Biology for 2023. The journal, identified by its ISSN 0831-2796 and E-ISSN 1480-3321, publishes innovative studies that span from 1987 to 2024, ensuring a rich historical context while addressing contemporary challenges in the field. Researchers and professionals are encouraged to contribute and engage with content that shapes the landscape of genetic research. Although the journal does not currently provide open access, it remains a vital resource for those committed to the exploration of genomic sciences, making it an essential read for both seasoned researchers and students alike.

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

NATURE REVIEWS GENETICS, published by NATURE PORTFOLIO, stands as a leading journal in the field of genetics, boasting a remarkable reputation reflected in its Q1 ranking across multiple categories including Genetics, Clinical Genetics, and Molecular Biology. With an impressive percentile of 99th in both Genetics and Clinical Genetics, as well as a solid rank in Molecular Biology, this journal is pivotal for researchers, professionals, and students alike who seek to stay informed on the latest advancements and comprehensive reviews in genetic research. The journal's scope encompasses a wide array of topics, providing in-depth insights from fundamental genetic principles to clinical applications, underscoring its importance in bridging basic science and medical practice. Though not an open-access publication, it remains accessible through various academic institutions, enhancing its reach and influence within the scientific community. With publication years spanning from 2000 to 2024, NATURE REVIEWS GENETICS continues to shape the future of genetics research and education.

GENES TO CELLS is a distinguished peer-reviewed journal published by Wiley, offering valuable insights into the intricate world of cell biology and genetics. With an ISSN of 1356-9597 and an E-ISSN of 1365-2443, this journal has been contributing to the academic community since its inception in 1996 and will continue its publishing journey until 2024. Recognized with a category quartile ranking of Q3 in both Cell Biology and Genetics, and Q2 in Medicine (Miscellaneous) as of 2023, it serves as an important platform for disseminating innovative research and reviews in molecular biology and related fields. Although it does not currently offer open access, the journal caters to a diverse readership by providing comprehensive studies that are essential for professionals, researchers, and students aiming to deepen their understanding of genetic mechanisms and cellular functions. Situated in the United Kingdom, GENES TO CELLS continues to play a pivotal role in shaping the future of biological research.